Table 4.
Interactions of Time and Age With Biomarker Concentrations of the ACL Injury Group a
| B (95% CI) | P Value | |
|---|---|---|
| Serum ARGS-aggrecan | ||
| Time | −0.132 (−0.182 to −0.081) | <.001 |
| Age at baseline | −0.015 (−0.020 to −0.010) | <.001 |
| Urine NTX-I | ||
| Time | −36 (−53 to −18) | <.001 |
| Age at baseline | −4 (−6 to −3) | <.001 |
| Urine CTX-II | ||
| Time | −2150 (−3370 to −930) | .001 |
| Age at baseline | −234 (−342 to −126) | <.001 |
a
Only markers with a significant interaction with age are shown. ACL, anterior cruciate ligament; ARGS-aggrecan, aggrecan ARGS neoepitope; CTX-II, C-terminal cross-linked telopeptide of type II collagen; NTX-I, N-terminal cross-linked telopeptide of type I collagen.